Investigator-Initiated Research (IIR)
Forecasted
Investigator-Initiated Research (IIR) supports independent investigators with funding, study drug, or data and samples for research addressing unmet patient needs or important scientific questions.
Funder: Biogen
Due Dates (Anticipated): January 2027 (Quarterly submission) | April 2027 (Quarterly submission) | July 2027 (Quarterly submission) | October 2027 (Quarterly submission)
Funding Amounts: Up to $300,000 USD, including indirect costs, for up to two years from contract finalization
Summary: Supports independently developed research through funding, study drug, or access to Biogen data and banked samples.
Key Information: The investigator serves as the study’s regulatory sponsor or accountable party and assumes responsibility for initiating and conducting it.
Description
Biogen’s Investigator-Initiated Research (IIR) program supports independently generated preclinical, clinical, outcomes-related, and disease-state research that Biogen has not solicited. Support can include funding, study drug, and access to Biogen datasets and banked laboratory samples. Eligible study types include clinical interventional and non-interventional research, nonclinical studies, and analysis of existing data.
Biogen prioritizes proposals aligned with its research objectives and published areas of interest, with scientific rigor and a credible prospect of achieving their objectives. Studies should address an unmet patient need or important scientific question and generate results suitable for peer-reviewed publication. Biogen also values inclusion of special populations and research that improves understanding of health inequities, enhancing the rigor and applicability of medical findings.
